Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
2002 1
2005 2
2007 2
2008 6
2009 2
2010 6
2011 5
2012 5
2013 11
2014 7
2015 9
2016 14
2017 9
2018 9
2019 12
2020 10
2021 23
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

112 results
Results by year
Filters applied: . Clear all
Page 1
Cancer immunotherapies targeting the PD-1 signaling pathway.
Iwai Y, Hamanishi J, Chamoto K, Honjo T. Iwai Y, et al. Among authors: hamanishi j. J Biomed Sci. 2017 Apr 4;24(1):26. doi: 10.1186/s12929-017-0329-9. J Biomed Sci. 2017. PMID: 28376884 Free PMC article. Review.
PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. Hamanishi J, et al. Int J Clin Oncol. 2016 Jun;21(3):462-73. doi: 10.1007/s10147-016-0959-z. Epub 2016 Feb 22. Int J Clin Oncol. 2016. PMID: 26899259 Free PMC article. Review.
Tumor Immune Microenvironment during Epithelial-Mesenchymal Transition.
Taki M, Abiko K, Ukita M, Murakami R, Yamanoi K, Yamaguchi K, Hamanishi J, Baba T, Matsumura N, Mandai M. Taki M, et al. Among authors: hamanishi j. Clin Cancer Res. 2021 Sep 1;27(17):4669-4679. doi: 10.1158/1078-0432.CCR-20-4459. Epub 2021 Apr 7. Clin Cancer Res. 2021. PMID: 33827891 Free article. Review.
Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H, Wei S, Hurt EM, Green MD, Zhao L, Vatan L, Szeliga W, Herbst R, Harms PW, Fecher LA, Vats P, Chinnaiyan AM, Lao CD, Lawrence TS, Wicha M, Hamanishi J, Mandai M, Kryczek I, Zou W. Lin H, et al. Among authors: hamanishi j. J Clin Invest. 2018 Feb 1;128(2):805-815. doi: 10.1172/JCI96113. Epub 2018 Jan 16. J Clin Invest. 2018. PMID: 29337305 Free PMC article.
Safety and Antitumor Activity of Anti-PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer.
Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, Matsumura N, Abiko K, Baba T, Yamaguchi K, Ueda A, Hosoe Y, Morita S, Yokode M, Shimizu A, Honjo T, Konishi I. Hamanishi J, et al. J Clin Oncol. 2015 Dec 1;33(34):4015-22. doi: 10.1200/JCO.2015.62.3397. Epub 2015 Sep 8. J Clin Oncol. 2015. PMID: 26351349 Clinical Trial.
Reply to D.-C. Mo et al.
Hamanishi J. Hamanishi J. J Clin Oncol. 2021 Dec 10:JCO2102636. doi: 10.1200/JCO.21.02636. Online ahead of print. J Clin Oncol. 2021. PMID: 34890244 No abstract available.
Immune checkpoint inhibition in ovarian cancer.
Hamanishi J, Mandai M, Konishi I. Hamanishi J, et al. Int Immunol. 2016 Jul;28(7):339-48. doi: 10.1093/intimm/dxw020. Epub 2016 Apr 7. Int Immunol. 2016. PMID: 27055470 Review.
112 results